February 23rd 2023
A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.
May 30th 2019
May 22nd 2019
Prevention and Early Detection of Tardive DyskinesiaJune 25th 2021
In this custom video series, Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, shares advice that can be helpful to community providers who manage children and adult patients prescribed antipsychotic therapy about screening for involuntary body movements and early signs of tardive dyskinesia.
Treating Tardive Dyskinesia With a VMAT2 InhibitorJune 25th 2021
In this custom video series, recommendations regarding patient selection and use of VMAT2 inhibitors in patients with tardive dyskinesia based on current clinical guidelines and real-world practice are shared.
Anticholinergic Medications and Impaired CognitionJune 25th 2021
In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, caution against the use of anticholinergic medications for Parkinson’s disease and comment on the use of alternative therapies for appropriate patients.
Managing Patients on Antipsychotic TherapyJune 25th 2021
In this custom video series, experts provide insight into strategies that may be helpful to healthcare professionals who manage patients on antipsychotic therapy to best monitor for signs of tardive dyskinesia, with special considerations regarding telepsychiatry.
Assessing Severity of Tardive DyskinesiaJune 25th 2021
In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, reference the Abnormal Involuntary Movement Scale (AIMS) rating scale, used to assess the severity of involuntary movements and help diagnose tardive dyskinesia.
Screening for Tardive Dyskinesia and Intervening With VMAT2 InhibitorsJune 25th 2021
In this custom video series, key opinion leaders discuss what to know about the use of antipsychotic therapy and screening for signs of tardive dyskinesia, and starting treatment with a VMAT2 inhibitor.